Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.
Pouyan N, Halvaei Khankahdani Z, Younesi Sisi F, Lee Y, Rosenblat JD, Teopiz KM, Lui LMW, Subramaniapillai M, Lin K, Nasri F, Rodrigues N, Gill H, Lipsitz O, Cao B, Ho R, Castle D, McIntyre RS. Pouyan N, et al. Among authors: lipsitz o. CNS Drugs. 2022 Oct;36(10):1031-1047. doi: 10.1007/s40263-022-00944-y. Epub 2022 Sep 12. CNS Drugs. 2022. PMID: 36097251 Free PMC article.
The emerging role of psilocybin and MDMA in the treatment of mental illness.
Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS. Gill H, et al. Among authors: lipsitz o. Expert Rev Neurother. 2020 Dec;20(12):1263-1273. doi: 10.1080/14737175.2020.1826931. Epub 2020 Sep 30. Expert Rev Neurother. 2020. PMID: 32954860 Review.
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.
Ceban F, Rosenblat JD, Kratiuk K, Lee Y, Rodrigues NB, Gill H, Subramaniapillai M, Nasri F, Lui LMW, Lipsitz O, Kumar A, Lee JG, Chau EH, Cao B, Lin K, Ho RC, Mansur RB, Swainson J, McIntyre RS. Ceban F, et al. Among authors: lipsitz o. CNS Drugs. 2021 Sep;35(9):925-934. doi: 10.1007/s40263-021-00846-5. Epub 2021 Aug 7. CNS Drugs. 2021. PMID: 34363603 Review.
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, Lipsitz O, Gill H, Subramaniapillai M, Mansur RB, Lin K, Ho R, Rosenblat JD, Castle D, McIntyre RS. Ling S, et al. Among authors: lipsitz o. CNS Drugs. 2022 Jan;36(1):17-30. doi: 10.1007/s40263-021-00877-y. Epub 2021 Nov 17. CNS Drugs. 2022. PMID: 34791625 Review.
The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS, Rodrigues NB, Lipsitz O, Nasri F, Gill H, Lui LM, Subramaniapillai M, Kratiuk K, Teopiz K, Ho R, Lee Y, Mansur RB, Rosenblat JD. McIntyre RS, et al. Among authors: lipsitz o. J Psychopharmacol. 2021 Feb;35(2):128-136. doi: 10.1177/0269881120954048. Epub 2020 Oct 11. J Psychopharmacol. 2021. PMID: 33040665
50 results